Fokdal Lars, Ørtoft Gitte, Hansen Estrid S, Røhl Lisbeth, Pedersen Erik Morre, Tanderup Kari, Lindegaard Jacob Christian
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Department of Gynaecology, Aarhus University Hospital, Aarhus, Denmark.
Brachytherapy. 2014 Nov-Dec;13(6):554-61. doi: 10.1016/j.brachy.2014.06.004. Epub 2014 Jul 20.
To evaluate clinical outcome and feasibility of a four-dimensional image-guided adaptive brachytherapy concept in patients with locally recurrent endometrial cancer.
Forty-three patients with locally recurrent endometrial cancer were included. Treatment consisted of conformal external beam radiotherapy followed by a boost using pulsed-dose-rate brachytherapy (BT). Large tumors were treated with MRI-guided interstitial BT. Small tumors were treated with CT-guided intracavitary BT. The planning aim (total external beam radiotherapy and BT) for high-risk clinical target volume was D90 > 80 Gy, whereas constraints for organs at risk were D2cc ≤ 90 Gy for bladder and D2cc ≤ 70 Gy for rectum, sigmoid, and bowel in terms of equivalent dose in 2 Gy fractions.
Median high-risk clinical target volume was 18 cm(3) (range, 0-91). D90 was 82 Gy (range, 77-88). D2cc to bladder, rectum, and sigmoid were 67 Gy (range, 50-81), 67 Gy (range, 51-77), and 55 Gy (range, 44-68), respectively. Median followup was 30 months (6-88). Two-year local control rate was 92% (standard error [SE], 5). Disease-free survival rate and overall survival rate was 59% (SE, 8) and 78% (SE, 7), respectively. Patients with low- to intermediate-risk for recurrence had a 2-year disease-free survival rate of 72% (SE, 9) compared with 42% (SE, 12) in patients with high risk for recurrence (p = 0.04). Late morbidity Grade 3 was recorded in 5 (12%) patients.
Four-dimensional image-guided adaptive brachytherapy is feasible in locally recurrent endometrial cancer. Local control rate is good. Systemic control remains a problem in patients with high risk for recurrence.
评估四维图像引导的适形近距离放射治疗概念在局部复发性子宫内膜癌患者中的临床疗效和可行性。
纳入43例局部复发性子宫内膜癌患者。治疗包括适形外照射放疗,随后采用脉冲剂量率近距离放射治疗(BT)进行增敏。大肿瘤采用MRI引导的组织间BT治疗。小肿瘤采用CT引导的腔内BT治疗。高危临床靶区的计划目标(总外照射放疗和BT)为D90>80 Gy,而危及器官的限制条件是膀胱的D2cc≤90 Gy,直肠、乙状结肠和肠道的D2cc≤70 Gy(以2 Gy分次的等效剂量计)。
高危临床靶区的中位体积为18 cm³(范围0 - 91)。D90为82 Gy(范围77 - 88)。膀胱、直肠和乙状结肠的D2cc分别为67 Gy(范围50 - 81)、67 Gy(范围51 - 77)和55 Gy(范围44 - 68)。中位随访时间为30个月(6 - 88)。两年局部控制率为92%(标准误[SE],5)。无病生存率和总生存率分别为59%(SE,8)和78%(SE,7)。复发低至中度风险的患者两年无病生存率为72%(SE,9),而复发高风险患者为42%(SE,12)(p = 0.04)。5例(12%)患者出现3级晚期并发症。
四维图像引导的适形近距离放射治疗在局部复发性子宫内膜癌中是可行的。局部控制率良好。对于复发高风险患者,全身控制仍然是一个问题。